Humacyte Q2 2026: $36.8M Loss, Going Concern Warning, and Nasdaq Delisting Notice
HUMA sits 20% above its 52-week low of $0.547.
Summary
Humacyte reported a $36.8M Q2 loss, reiterated going concern doubts, and disclosed a Nasdaq delisting notice and CEO stock sale plan.
Key Events · Earnings and Guidance · HUMA
-
Q2 Net Loss of $36.8M
Humacyte reported a net loss of $36.8 million for Q2 2026 and $54.4 million for the first half of 2026, with cash and cash equivalents of $79.9 million as of June 30, 2026.
-
Going Concern Warning Reiterated
The company stated it 'will not have sufficient liquidity to fund its operations beyond one year' without additional capital or sufficient commercial sales, raising substantial doubt about its ability to continue as a going concern.
-
Nasdaq Delisting Notice
On July 31, 2026, Humacyte received a Nasdaq delisting notice after its stock closed below $1.00 for 30 consecutive business days. The company has until January 27, 2027, to regain compliance.
-
CEO 10b5-1 Trading Plan
CEO Laura Niklason adopted a Rule 10b5-1 trading plan on June 3, 2026, allowing potential sale of up to 214,420 shares starting September 1, 2026.
Analysis · HUMA · Life Sciences
Humacyte's Q2 2026 10-Q reveals a $36.8 million quarterly net loss and reiterates a going concern warning, stating it lacks sufficient liquidity to fund operations beyond one year. The company also disclosed a Nasdaq delisting notice received July 31, 2026, and a CEO 10b5-1 plan to sell up to 214,420 shares. These disclosures confirm severe financial distress and regulatory risk, making this filing highly material for investors.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HUMA was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $179.3M. The 52-week trading range was $0.55 to $2.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.